Ballentine Partners, LLC Halozyme Therapeutics, Inc. Transaction History
Ballentine Partners, LLC
- $5.81 Billion
- Q3 2024
A detailed history of Ballentine Partners, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Ballentine Partners, LLC holds 6,438 shares of HALO stock, worth $303,616. This represents 0.01% of its overall portfolio holdings.
Number of Shares
6,438
Previous 6,419
0.3%
Holding current value
$303,616
Previous $336,000
9.52%
% of portfolio
0.01%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding HALO
# of Institutions
543Shares Held
125MCall Options Held
294KPut Options Held
180K-
Black Rock Inc. New York, NY17.6MShares$831 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$608 Million0.01% of portfolio
-
State Street Corp Boston, MA6.63MShares$313 Million0.02% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.06MShares$192 Million5.07% of portfolio
-
Alliancebernstein L.P. New York, NY3.41MShares$161 Million0.07% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $6.57B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...